ArticleMaterials today. Bio2026
Programming Mn(II) coordination in self-assembling peptides amplifies mtDNA-driven STING signaling for potent antitumor immunity.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of the cGAS-STING pathway is a powerful antitumor strategy, but its therapeutic performance is often constrained by insufficient cytosolic DNA cues. Here, we report a bioinspired metallopeptide nanoassembly, RKLAHE-Mn, formed through dynamic N,O-bidentate coordination between Mn(II) and a programmable hexapeptide scaffold. By leveraging specific interactions between histidine and glutamic acid, we achieve robust chelation that orchestrates the self-assembly of uniform, chain-like assemblies of spherical nanoparticles, with DFT calculations supporting a thermodynamically favorable Mn-His/Glu N,O-coordination mode. Upon internalization, RKLAHE-Mn triggers a rapid ROS burst and perturbs intracellular redox homeostasis. These cationic assemblies preferentially accumulate in mitochondria, leading to loss of mitochondrial membrane potential and promoting mitochondrial DNA (mtDNA) leakage into the cytosol. The released mtDNA, together with Mn(II)-dependent potentiation, amplifies STING signaling and elicits immunogenic cell death-associated responses. Notably, RKLAHE-Mn also potentiates STING-related innate immune signaling in dendritic cells, driving maturation with upregulated CD80, CD86, and MHC class II expression, increased secretion of IL-6, TNF-α, and CXCL10, and enhanced antigen presentation and cross-presentation. In a murine breast cancer model, RKLAHE-Mn remodels the immunosuppressive tumor microenvironment by promoting dendritic cell maturation and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.